

# Gary Maartens

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/8655722/publications.pdf](https://exaly.com/author-pdf/8655722/publications.pdf)

Version: 2024-02-01

301  
papers

16,546  
citations

17319

63  
h-index

22041

114  
g-index

372  
all docs

372  
docs citations

372  
times ranked

16776  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir With Rifampicin. <i>Clinical Infectious Diseases</i> , 2024, 78, 1246-1255.	5.7	2
2	A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus-associated Tuberculous Meningitis: The LASER-TBM Trial. <i>Clinical Infectious Diseases</i> , 2023, 76, 1412-1422.	5.7	11
3	Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial. <i>Clinical Infectious Diseases</i> , 2023, 76, 1832-1840.	5.7	5
4	Analysis of serum microRNA-122 in a randomized controlled trial of N-acetylcysteine for treatment of antituberculosis drug-induced liver injury. <i>British Journal of Clinical Pharmacology</i> , 2023, 89, 1844-1851.	2.3	3
5	Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 821-830.	2.5	3
6	Weight gain on dolutegravir: Association is not the same as causation. <i>Southern African Journal of HIV Medicine</i> , 2023, 24, .	0.9	4
7	Validation of a quantitative liquid chromatography tandem mass spectrometry assay for linezolid in cerebrospinal fluid and its application to patients with HIV-associated TB-meningitis. <i>Heliyon</i> , 2023, 9, e21962.	3.3	1
8	Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 496-506.	8.9	58
9	Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 507-518.	8.9	41
10	Optimized Loading Dose Strategies for Bedaquiline When Restarting Interrupted Drug-Resistant Tuberculosis Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0174921.	3.4	1
11	Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1146-1154.	3.2	19
12	Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa. <i>Journal of Infectious Diseases</i> , 2022, 226, 147-156.	3.9	9
13	Risk of Immune Reconstitution Inflammatory Syndrome With Integrase Inhibitors Versus Other Classes of Antiretrovirals: A Systematic Review and Meta-analysis of Randomized Trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, 232-239.	2.2	10
14	An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1214-1227.	6.6	50
15	A treatment recommender clinical decision support system for personalized medicine: method development and proof-of-concept for drug resistant tuberculosis. <i>BMC Medical Informatics and Decision Making</i> , 2022, 22, 56.	3.1	11
16	Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB). <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1720-1724.	3.2	15
17	Effect of dihydroartemisinin/piperaquine for malaria intermittent preventive treatment on dolutegravir exposure in pregnant women living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1733-1737.	3.2	4
18	Tuberculosis screening among HIV-positive inpatients: a systematic review and individual participant data meta-analysis. <i>Lancet HIV</i> , the, 2022, 9, e233-e241.	4.6	20

#	ARTICLE	IF	CITATIONS
19	Simultaneous Determination of Carvedilol, Enalaprilat, and Perindoprilat in Human Plasma Using LC-MS/MS and Its Application to a Pharmacokinetic Pilot Study. <i>Chromatographia</i> , 2022, 85, 455-468.	1.3	2
20	Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1042-1051.	8.9	35
21	Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2022, 226, 1616-1625.	3.9	3
22	Diagnostic accuracy of WHO screening criteria to guide lateral-flow lipoarabinomannan testing among HIV-positive inpatients: A systematic review and individual participant data meta-analysis. <i>Journal of Infection</i> , 2022, 85, 40-48.	3.4	8
23	The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0013622.	3.4	1
24	Xpert Ultra testing of blood in severe HIV-associated tuberculosis to detect and measure Mycobacterium tuberculosis blood stream infection: a diagnostic and disease biomarker cohort study. <i>Lancet Microbe</i> , The, 2022, 3, e521-e532.	6.7	12
25	Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	3.4	9
26	Determining antenatal medicine exposures in South African women: a comparison of three methods of ascertainment. <i>BMC Pregnancy and Childbirth</i> , 2022, 22, .	2.4	2
27	Rechallenge after anti-tuberculosis drug-induced liver injury in a high HIV prevalence cohort. <i>Southern African Journal of HIV Medicine</i> , 2022, 23, .	0.9	3
28	Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	3
29	Dolutegravir for second-line treatment: Programmatic implications of new evidence. <i>Southern African Journal of HIV Medicine</i> , 2022, 23, .	0.9	3
30	Diagnosis and treatment of opioid-related disorders in a South African private sector medical insurance scheme: A cohort study. <i>International Journal of Drug Policy</i> , 2022, 109, 103853.	3.5	4
31	Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	3.4	2
32	Introduction to the special issue on integration of human factors and ergonomics. <i>EURO Journal on Transportation and Logistics</i> , 2022, 11, 100098.	2.2	0
33	<i>CYP2B6</i> Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. <i>Clinical Infectious Diseases</i> , 2021, 73, e3902-e3909.	5.7	62
34	Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. <i>Clinical Infectious Diseases</i> , 2021, 73, e2005-e2015.	5.7	440
35	A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-tuberculosis Drug-Induced Liver Injury. <i>Clinical Infectious Diseases</i> , 2021, 73, e3377-e3383.	5.7	22
36	Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial. <i>Wellcome Open Research</i> , 2021, 6, 1.	1.9	11

#	ARTICLE	IF	CITATIONS
37	Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 87, 1002-1009.	2.2	6
38	Adult medical emergency unit presentations due to adverse drug reactions in a setting of high HIV prevalence. <i>African Journal of Emergency Medicine</i> , 2021, 11, 46-52.	1.2	3
39	Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid. <i>Southern African Journal of HIV Medicine</i> , 2021, 22, 1206.	0.9	3
40	Diagnostic Accuracy of the INSHI Consensus Case Definition for the Diagnosis of Paradoxical Tuberculosis-IRIS. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 86, 587-592.	2.2	7
41	Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. <i>International Journal of Infectious Diseases</i> , 2021, 105, 688-694.	3.3	25
42	Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 2083-2092.	5.7	27
43	Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen. <i>Aids</i> , 2021, 35, 1423-1432.	2.2	35
44	Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0268720.	3.4	17
45	QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 975-983.	8.9	66
46	Undisclosed HIV status and antiretroviral therapy use among South African blood donors. <i>Transfusion</i> , 2021, 61, 2392-2400.	1.8	11
47	Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0014021.	3.4	25
48	Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0239920.	3.4	12
49	Linezolid Population Pharmacokinetics in South African Adults with Drug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0138121.	3.4	11
50	Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0027821.	3.4	4
51	Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. <i>Lancet HIV</i> , the, 2021, 8, e8-e15.	4.6	36
52	Etiology of Pulmonary Infections in Human Immunodeficiency Virus-associated Inpatients Using Sputum Multiplex Real-time Polymerase Chain Reaction. <i>Clinical Infectious Diseases</i> , 2020, 70, 1147-1152.	5.7	15
53	Managing Human Immunodeficiency Virus-associated Tuberculosis in the Dolutegravir Era. <i>Clinical Infectious Diseases</i> , 2020, 70, 557-558.	5.7	0
54	Point-of-Care Ultrasound Predictors for the Diagnosis of Tuberculosis in HIV-Positive Patients Presenting to an Emergency Center. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 83, 415-423.	2.2	13

#	ARTICLE	IF	CITATIONS
55	Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis. <i>International Journal of Audiology</i> , 2020, 59, 219-223.	2.1	7
56	Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2020, 7, e666-e676.	4.6	165
57	Clofazimine pharmacokinetics in patients with TB: dosing implications. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3269-3277.	3.2	37
58	Diagnosing lymphoma in the shadow of an epidemic: lessons learned from the diagnostic challenges posed by the dual tuberculosis and HIV epidemics. <i>Leukemia and Lymphoma</i> , 2020, 61, 3417-3421.	1.4	8
59	CheXaid: deep learning assistance for physician diagnosis of tuberculosis using chest x-rays in patients with HIV. <i>Npj Digital Medicine</i> , 2020, 3, 115.	11.3	76
60	Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.4	14
61	Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?. <i>European Respiratory Journal</i> , 2020, 56, 2001369.	7.5	7
62	Mycobacterium tuberculosis bloodstream infection prevalence, diagnosis, and mortality risk in seriously ill adults with HIV: a systematic review and meta-analysis of individual patient data. <i>Lancet Infectious Diseases</i> , 2020, 20, 742-752.	8.9	39
63	Diagnostic accuracy of the Xpert MTB/Rif Ultra for tuberculosis adenitis. <i>BMC Infectious Diseases</i> , 2020, 20, 33.	3.0	23
64	Safety and Effectiveness of Isoniazid Preventive Therapy in Pregnant Women Living with Human Immunodeficiency Virus on Antiretroviral Therapy: An Observational Study Using Linked Population Data. <i>Clinical Infectious Diseases</i> , 2020, 71, e351-e358.	5.7	23
65	Pharmacokinetic profile and safety of adjusted doses of darunavir/ritonavir with rifampicin in people living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1019-1025.	3.2	12
66	Correlation of Linezolid Hair Concentrations with Plasma Exposure in Patients with Drug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.4	2
67	A Clinical Prediction Score Including Trial of Antibiotics and C-Reactive Protein to Improve the Diagnosis of Tuberculosis in Ambulatory People With HIV. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz543.	0.9	13
68	Increased Mortality With Delayed and Missed Switch to Second-Line Antiretroviral Therapy in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 107-113.	2.2	18
69	Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy. <i>Southern African Journal of HIV Medicine</i> , 2020, 21, 1062.	0.9	11
70	Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update. <i>Southern African Journal of HIV Medicine</i> , 2020, 21, 1115.	0.9	37
71	â€œCovering the tailâ€™ after stopping efavirenz-based antiretroviral therapy. <i>Southern African Journal of HIV Medicine</i> , 2020, 21, 1036.	0.9	1
72	A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 875-882.	2.5	26

#	ARTICLE	IF	CITATIONS
73	Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases. <i>BMC Infectious Diseases</i> , 2019, 19, 544.	3.0	26
74	Management of active tuberculosis in adults with HIV. <i>Lancet HIV</i> , the, 2019, 6, e463-e474.	4.6	47
75	Clinical, microbiologic, and immunologic determinants of mortality in hospitalized patients with HIV-associated tuberculosis: A prospective cohort study. <i>PLoS Medicine</i> , 2019, 16, e1002840.	8.4	54
76	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 820-826.	10.4	97
77	Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.4	1
78	The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic setting. <i>BMC Cancer</i> , 2019, 19, 384.	2.6	18
79	Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2377-2384.	3.2	33
80	Abdominal Ultrasound for the Diagnosis of Tuberculosis Among Human Immunodeficiency Virus-Positive Inpatients With World Health Organization Danger Signs. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz094.	0.9	14
81	Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 202-206.	3.3	39
82	Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1670-1678.	3.2	48
83	Discovery of False Elite Controllers: HIV Antibody-Positive RNA-Negative Blood Donors Found To Be on Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2019, 220, 643-647.	3.9	27
84	Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting. <i>Aids</i> , 2019, 33, 525-536.	2.2	9
85	Emtricitabine-associated red cell aplasia. <i>Aids</i> , 2019, 33, 1095-1096.	2.2	6
86	A Clinical Prediction Rule for Protease Inhibitor Resistance in Patients Failing Second-Line Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 325-329.	2.2	10
87	Brief Report: Real-World Performance and Interobserver Agreement of Urine Lipoarabinomannan in Diagnosing HIV-Associated Tuberculosis in an Emergency Center. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, e10-e14.	2.2	8
88	A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 311-318.	2.2	32
89	Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 73-78.	2.2	39
90	Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 699-709.	3.2	14

#	ARTICLE	IF	CITATIONS
91	Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.4	19
92	Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 564-571.	6.6	22
93	Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus <sup>1</sup> . <i>Clinical Infectious Diseases</i> , 2019, 69, 295-305.	5.7	10
94	Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals. <i>The Cochrane Library</i> , 2019, 2019, CD012777.	2.8	25
95	Rivalit <sup>®</sup> s et arrangements coopératifs pour lâ€™acc <sup>™</sup> s lâ€™eau souterraine dans la plaine de Berrechid au Maroc. <i>Cahiers Agricultures</i> , 2019, 28, 4.	1.1	3
96	Correlation of hair and plasma efavirenz concentrations in HIV-positive South Africans. <i>Southern African Journal of HIV Medicine</i> , 2019, 20, 881.	0.9	7
97	Co-treatment of Tuberculosis and HIV: Pharmacologic Considerations. , 2019, , 239-267.		0
98	Optimizing Tuberculosis Diagnosis in Human Immunodeficiency Virus <sup>1</sup> -Infected Inpatients Meeting the Criteria of Seriously Ill in the World Health Organization Algorithm. <i>Clinical Infectious Diseases</i> , 2018, 66, 1419-1426.	5.7	22
99	Erratum to South African guideline for the management of community-acquired pneumonia in adults. <i>Journal of Thoracic Disease</i> , 2018, 10, E673-E675.	1.4	3
100	Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. <i>New England Journal of Medicine</i> , 2018, 379, 1915-1925.	30.1	149
101	Evaluation of Tuberculosis Treatment Response With Serial C-Reactive Protein Measurements. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy253.	0.9	21
102	Incremental yield and cost of urine Determine TB-LAM and sputum induction in seriously ill adults with HIV. <i>International Journal of Infectious Diseases</i> , 2018, 75, 67-73.	3.3	24
103	High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. <i>European Respiratory Journal</i> , 2018, 52, 1801528.	7.5	96
104	The Next Generation Scientist program: capacity-building for future scientific leaders in low- and middle-income countries. <i>BMC Medical Education</i> , 2018, 18, 233.	2.5	20
105	Routine data underestimates the incidence of first-line antiretroviral drug discontinuations due to adverse drug reactions: Observational study in two South African cohorts. <i>PLoS ONE</i> , 2018, 13, e0203530.	2.5	3
106	Anthropometric definitions for antiretroviral-associated lipodystrophy derived from a longitudinal South African cohort with serial dual-energy X-ray absorptiometry measurements. <i>International Journal of STD and AIDS</i> , 2018, 29, 1194-1203.	1.2	5
107	Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. <i>Lancet Respiratory Medicine</i> , 2018, 6, 699-706.	10.4	198
108	Prognostic indicators in the World Health Organization <sup>™</sup> s algorithm for seriously ill HIV-infected inpatients with suspected tuberculosis. <i>AIDS Research and Therapy</i> , 2018, 15, 5.	1.8	11

#	ARTICLE	IF	CITATIONS
109	C-reactive protein and procalcitonin to discriminate between tuberculosis, <i>Pneumocystis jirovecii</i> pneumonia, and bacterial pneumonia in HIV-infected inpatients meeting WHO criteria for seriously ill: a prospective cohort study. <i>BMC Infectious Diseases</i> , 2018, 18, 399.	3.0	25
110	Development of a clinical prediction rule to diagnose <i>Pneumocystis jirovecii</i> pneumonia in the World Health Organization's algorithm for seriously ill HIV-infected patients. <i>Southern African Journal of HIV Medicine</i> , 2018, 19, 851.	0.9	9
111	Hemostatic changes associate with mortality in hospitalized patients with HIV-associated tuberculosis: a prospective cohort study. <i>Journal of Infectious Diseases</i> , 2017, 215, jiw532.	3.9	19
112	Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial. <i>AIDS Research and Therapy</i> , 2017, 14, 6.	1.8	8
113	Brief Report: Late Efavirenz-Induced Ataxia and Encephalopathy: A Case Series. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 577-579.	2.2	21
114	Mortality in Severe Human Immunodeficiency Virus-Tuberculosis Associates With Innate Immune Activation and Dysfunction of Monocytes. <i>Clinical Infectious Diseases</i> , 2017, 65, 73-82.	5.7	20
115	The Cape Town Clinical Decision Rule for Streptococcal Pharyngitis in Children. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 250-255.	2.0	17
116	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , 2017, 5, 291-360.	10.4	478
117	Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 212-217.	3.3	38
118	Changes in estimated glomerular filtration rate over time in South African HIV-infected patients receiving tenofovir: a retrospective cohort study. <i>Journal of the International AIDS Society</i> , 2017, 20, 21317.	3.1	34
119	Resistance matters in EARNEST. <i>Lancet HIV</i> , 2017, 4, e323-e324.	4.6	6
120	Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 355-358.	4.0	27
121	Second-Line Antiretroviral Therapy in Sub-Saharan Africa: It Is Time to Mind the Gaps. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 1181-1184.	1.2	42
122	Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poor setting: which best predicts virological and resistance outcomes?. <i>AIDS Research and Therapy</i> , 2017, 14, 20.	1.8	56
123	Factors associated with loss to follow-up after occupational HIV exposure in Cape Town, South Africa: a retrospective cohort study. <i>AIDS Research and Therapy</i> , 2017, 14, 23.	1.8	3
124	Diagnostic Outcomes After Chest Radiograph Interpretation in Patients With Suspected Tuberculosis and Negative Sputum Smears in a High-Burden Human Immunodeficiency Virus and Tuberculosis Setting. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx123.	0.9	4
125	South African guideline for the management of community-acquired pneumonia in adults. <i>Journal of Thoracic Disease</i> , 2017, 9, 1469-1502.	1.4	64
126	First-line antiretroviral drug discontinuations in children. <i>PLoS ONE</i> , 2017, 12, e0169762.	2.5	7



#	ARTICLE	IF	CITATIONS
127	Interrater agreement of two adverse drug reaction causality assessment methods: A randomised comparison of the Liverpool Adverse Drug Reaction Causality Assessment Tool and the World Health Organization-Uppsala Monitoring Centre system. <i>PLoS ONE</i> , 2017, 12, e0172830.	2.5	29
128	Clinician compliance with laboratory monitoring and prescribing guidelines in HIV-1-infected patients receiving tenofovir. <i>South African Medical Journal</i> , 2016, 106, 369.	0.8	4
129	Anti-Retroviral Therapy Increases the Prevalence of Dyslipidemia in South African HIV-Infected Patients. <i>PLoS ONE</i> , 2016, 11, e0151911.	2.5	38
130	Adverse Drug Reactions Causing Admission to Medical Wards. <i>Medicine (United States)</i> , 2016, 95, e3437.	1.1	62
131	Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy. <i>Aids</i> , 2016, 30, 1279-1286.	2.2	17
132	Cases of antiretroviral-associated gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa. <i>AIDS Research and Therapy</i> , 2016, 13, 40.	1.8	9
133	Prolonged tuberculosis-associated immune reconstitution inflammatory syndrome: characteristics and risk factors. <i>BMC Infectious Diseases</i> , 2016, 16, 518.	3.0	16
134	Moderate to severe HIV-associated neurocognitive impairment. <i>Medicine (United States)</i> , 2016, 95, e5401.	1.1	23
135	Effect of mid-dose efavirenz concentrations and CYP2B6 genotype on viral suppression in patients on first-line antiretroviral therapy. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 466-472.	3.3	25
136	Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1313-1319.	1.9	18
137	Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1493-1503.	3.2	26
138	Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 901-915.	4.5	69
139	Changes in Body Fat Distribution on Dual-Energy X-Ray Absorptiometry in Black South Africans Starting First-Line Antiretroviral Therapy. <i>AIDS Patient Care and STDs</i> , 2016, 30, 455-462.	2.7	10
140	Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, e378-e383.	2.0	4
141	Increased risk of dysglycaemia in South Africans with HIV; especially those on protease inhibitors. <i>Diabetes Research and Clinical Practice</i> , 2016, 119, 41-47.	2.8	37
142	Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 158-162.	3.3	16
143	Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 915-919.	1.2	20
144	Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1037-1040.	3.2	51

#	ARTICLE	IF	CITATIONS
145	Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy. <i>Medicine (United States)</i> , 2016, 95, e2844.	1.1	48
146	Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations. <i>Medicine (United States)</i> , 2016, 95, e2385.	1.1	32
147	Adverse Drug Reactions Reported to a National HIV & Tuberculosis Health Care Worker Hotline in South Africa: Description and Prospective Follow-Up of Reports. <i>Drug Safety</i> , 2016, 39, 159-169.	3.2	7
148	Preventing Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in High-Risk Patients: Protocol of a Randomized Placebo-Controlled Trial of Prednisone (PredART Trial). <i>JMIR Research Protocols</i> , 2016, 5, e173.	1.0	11
149	Southern African guidelines on the safe use of pre-exposure prophylaxis in persons at risk of acquiring HIV-1 infection. <i>Southern African Journal of HIV Medicine</i> , 2016, 17, 455.	0.9	80
150	The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients. <i>BMC Infectious Diseases</i> , 2015, 16, 30.	3.0	24
151	Independent predictors of tuberculosis mortality in a high HIV prevalence setting: a retrospective cohort study. <i>AIDS Research and Therapy</i> , 2015, 12, 35.	1.8	30
152	Changes in blood pressure, glucose levels, insulin secretion and anthropometry after long term exposure to antiretroviral therapy in South African women. <i>AIDS Research and Therapy</i> , 2015, 12, 24.	1.8	40
153	Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study. <i>AIDS Research and Therapy</i> , 2015, 12, 39.	1.8	28
154	A Randomized Controlled Trial of Real-Time Electronic Adherence Monitoring With Text Message Dosing Reminders in People Starting First-Line Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 495-502.	2.2	93
155	Updated recommendations for the management of upper respiratory tract infections in South Africa. <i>South African Medical Journal</i> , 2015, 105, 345.	0.8	16
156	Antiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans. <i>PLoS ONE</i> , 2015, 10, e0144286.	2.5	36
157	The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 1194-1196.	1.2	4
158	Linezolid for Treating Tuberculosis: A Delicate Balancing Act. <i>EBioMedicine</i> , 2015, 2, 1568-1569.	6.0	13
159	Cytotoxic Mediators in Paradoxical HIV-Associated Tuberculosis Immune Reconstitution Inflammatory Syndrome. <i>Journal of Immunology</i> , 2015, 194, 1748-1754.	0.8	32
160	Lower-dose efavirenz: what is needed before implementation?. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 749-751.	8.9	3
161	Central Nervous System Penetration of Antiretroviral Drugs: Pharmacokinetic, Pharmacodynamic and Pharmacogenomic Considerations. <i>Clinical Pharmacokinetics</i> , 2015, 54, 581-598.	3.6	63
162	Acute interstitial nephritis caused by lopinavir/ritonavir in a surgeon receiving antiretroviral postexposure prophylaxis. <i>Aids</i> , 2015, 29, 503-504.	2.2	10

#	ARTICLE	IF	CITATIONS
163	HIV-associated tuberculosis immune reconstitution inflammatory syndrome is characterized by Toll-like receptor and inflammasome signalling. <i>Nature Communications</i> , 2015, 6, 8451.	13.2	83
164	Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 979-985.	1.2	134
165	Guideline on the management of occupational and non-occupational exposure to the human immunodeficiency virus and recommendations for post-exposure prophylaxis: 2015 Update. <i>Southern African Journal of HIV Medicine</i> , 2015, 16, 399.	0.9	13
166	Southern African HIV Clinicians Society adult antiretroviral therapy guidelines: Update on when to initiate antiretroviral therapy. <i>Southern African Journal of HIV Medicine</i> , 2015, 16, 428.	0.9	14
167	Clinical Access Program for Bedaquiline for the treatment of drug-resistant tuberculosis. <i>South African Medical Journal</i> , 2014, 104, 164.	0.8	31
168	Tuberculosis preventive therapy: An underutilised strategy to reduce individual risk of TB and contribute to TB control. <i>South African Medical Journal</i> , 2014, 104, 339.	0.8	18
169	Short term adherence tool predicts failure on second line protease inhibitor-based antiretroviral therapy: an observational cohort study. <i>BMC Infectious Diseases</i> , 2014, 14, 664.	3.0	25
170	Matrix metalloproteinases and tissue damage in HIV-associated tuberculosis immune reconstitution inflammatory syndrome. <i>European Journal of Immunology</i> , 2014, 44, 127-136.	3.3	50
171	The development of simple anthropometric measures to diagnose antiretroviral therapy-associated lipodystrophy in resource limited settings. <i>AIDS Research and Therapy</i> , 2014, 11, 26.	1.8	7
172	Dosing of raltegravir when given with rifampicin. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 442-443.	8.9	3
173	Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2014, 384, 682-690.	12.1	233
174	HIV infection: epidemiology, pathogenesis, treatment, and prevention. <i>Lancet</i> , The, 2014, 384, 258-271.	12.1	635
175	Plasma Lopinavir Concentrations Predict Virological Failure in a Cohort of South African Children Initiating a Protease-Inhibitor-Based Regimen. <i>Antiviral Therapy</i> , 2014, 19, 399-406.	1.0	12
176	Diagnostic accuracy and clinical role of rapid C-reactive protein testing in HIV-infected individuals with presumed tuberculosis in South Africa. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 20-26.	1.2	42
177	Neuronal toxicity of efavirenz: a systematic review. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 841-846.	2.5	88
178	ART and tuberculosis: the final nail in nevirapine's coffin?. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 278-279.	8.9	0
179	The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals [Short communication]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 333-335.	1.2	13
180	A Time-to-Event Pharmacodynamic Model Describing Treatment Response in Patients with Pulmonary Tuberculosis Using Days to Positivity in Automated Liquid Mycobacterial Culture. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 789-795.	3.4	35

#	ARTICLE	IF	CITATIONS
181	Role of the Interleukin 10 Family of Cytokines in Patients With Immune Reconstitution Inflammatory Syndrome Associated With HIV Infection and Tuberculosis. <i>Journal of Infectious Diseases</i> , 2013, 207, 1148-1156.	3.9	30
182	Mitochondrial Genomics and Antiretroviral Therapy-Associated Metabolic Complications in HIV-Infected Black South Africans: A Pilot Study. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1031-1039.	1.2	17
183	Patient-Nominated, Community-Based HIV Treatment Supporters: Patient Perspectives, Feasibility, Challenges, and Factors for Success in HIV-Infected South African Adults. <i>AIDS Patient Care and STDs</i> , 2013, 27, 96-102.	2.7	38
184	Effect of Different Antiretroviral Drug Regimens on Body Fat Distribution of HIV-Infected South African Women. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 557-563.	1.2	29
185	In reply to "Serum C-reactive protein measurement for ruling out HIV-associated tuberculosis" [Correspondence]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 284-284.	1.2	0
186	Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype. <i>Aids</i> , 2013, 27, 1933-1940.	2.2	48
187	Clinical pharmacology becomes a specialty in South Africa. <i>South African Medical Journal</i> , 2013, 103, 150.	0.8	4
188	Complications of Antiretroviral Therapy Initiation in Hospitalised Patients with HIV-Associated Tuberculosis. <i>PLoS ONE</i> , 2013, 8, e54145.	2.5	17
189	A Novel Markov Model Projecting Costs and Outcomes of Providing Antiretroviral Therapy to Public Patients in Private Practices versus Public Clinics in South Africa. <i>PLoS ONE</i> , 2013, 8, e53570.	2.5	9
190	Impact of immune reconstitution inflammatory syndrome on antiretroviral therapy adherence. <i>Patient Preference and Adherence</i> , 2012, 6, 887.	1.9	17
191	Interferon release does not add discriminatory value to smear-negative HIV-tuberculosis algorithms. <i>European Respiratory Journal</i> , 2012, 39, 163-171.	7.5	26
192	Effect of Antiretroviral Therapy on the Diagnostic Accuracy of Symptom Screening for Intensified Tuberculosis Case Finding in a South African HIV Clinic. <i>Clinical Infectious Diseases</i> , 2012, 55, 1698-1706.	5.7	51
193	A model to rule out smear-negative tuberculosis among symptomatic HIV patients using C-reactive protein. <i>International Journal of Tuberculosis and Lung Disease</i> , 2012, 16, 1247-1251.	1.2	14
194	Global HIV/AIDS Clinical and Translational Pharmacology. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-3.	0.7	2
195	Should tuberculin skin testing be a prerequisite to prolonged IPT for HIV-infected adults? [Perspectives]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2012, 16, 857-859.	1.2	2
196	Diagnosis and treatment of pulmonary tuberculosis in patients with HIV. <i>Lancet Infectious Diseases</i> , 2012, 12, 267-268.	8.9	2
197	Corticosteroid-modulated Immune Activation in the Tuberculosis Immune Reconstitution Inflammatory Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 369-377.	6.6	75
198	Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study. <i>AIDS Research and Therapy</i> , 2012, 9, 32.	1.8	4

#	ARTICLE	IF	CITATIONS
199	Baseline Predictors of Sputum Culture Conversion in Pulmonary Tuberculosis: Importance of Cavities, Smoking, Time to Detection and W-Beijing Genotype. PLoS ONE, 2012, 7, e29588.	2.5	56
200	The Safety, Effectiveness and Concentrations of Adjusted Lopinavir/Ritonavir in HIV-Infected Adults on Rifampicin-Based Antitubercular Therapy. PLoS ONE, 2012, 7, e32173.	2.5	29
201	Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa. South African Medical Journal, 2012, 102, 506.	0.8	33
202	The role of the Infectious Diseases unit at Groote Schuur Hospital in addressing South Africa's greatest burden of disease. South African Medical Journal, 2012, 102, 528.	0.8	4
203	Guidelines for antiretroviral therapy in adults. Southern African Journal of HIV Medicine, 2012, 13, .	0.9	15
204	Pharmacogenomics of HIV Therapy: Summary of a Workshop Sponsored by the National Institute of Allergy and Infectious Diseases. HIV Clinical Trials, 2011, 12, 277-285.	2.0	15
205	Routine cryptococcal antigen screening for HIV-infected patients with low CD4+ T-lymphocyte counts - time to implement in South Africa?. South African Medical Journal, 2011, 101, 232.	0.8	20
206	Factors Influencing Retention in Care after Starting Antiretroviral Therapy in a Rural South African Programme. PLoS ONE, 2011, 6, e19201.	2.5	76
207	Effect of Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy on Dysglycemia and Insulin Sensitivity in South African HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 284-289.	2.2	75
208	Low Lopinavir Plasma or Hair Concentrations Explain Second-Line Protease Inhibitor Failures in a Resource-Limited Setting. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 333-339.	2.2	101
209	Evaluation of the World Health Organization algorithm for the diagnosis of HIV-associated sputum smear-negative tuberculosis. International Journal of Tuberculosis and Lung Disease, 2011, 15, 919-924.	1.2	34
210	Lopinavir Exposure is Insufficient in Children Given Double Doses of Lopinavir/Ritonavir during Rifampicin-Based Treatment for Tuberculosis. Antiviral Therapy, 2011, 16, 417-421.	1.0	54
211	Pharmacokinetics of Lopinavir in HIV-Infected Adults Receiving Rifampin with Adjusted Doses of Lopinavir-Ritonavir Tablets. Antimicrobial Agents and Chemotherapy, 2011, 55, 3195-3200.	3.4	50
212	Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. European Respiratory Journal, 2011, 37, 1248-1259.	7.5	132
213	The <i>SLCO1B1</i> rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications. Antimicrobial Agents and Chemotherapy, 2011, 55, 4122-4127.	3.4	134
214	Interaction between Artemether-Lumefantrine and Nevirapine-Based Antiretroviral Therapy in HIV-1-Infected Patients. Antimicrobial Agents and Chemotherapy, 2011, 55, 5616-5623.	3.4	58
215	The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial. American Journal of Clinical Nutrition, 2011, 93, 93-100.	4.6	57
216	Development of a Standardized Screening Rule for Tuberculosis in People Living with HIV in Resource-Constrained Settings: Individual Participant Data Meta-analysis of Observational Studies. PLoS Medicine, 2011, 8, e1000391.	8.4	331

#	ARTICLE	IF	CITATIONS
217	Performance of Serum C-Reactive Protein as a Screening Test for Smear-Negative Tuberculosis in an Ambulatory High HIV Prevalence Population. <i>PLoS ONE</i> , 2011, 6, e15248.	2.5	64
218	Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. <i>Aids</i> , 2010, 24, 563-572.	2.2	237
219	Association of Antiretroviral Therapy Adherence and Health Care Costs. <i>Annals of Internal Medicine</i> , 2010, 152, 18.	10.2	60
220	Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 1017-1023.	1.9	23
221	Improving the evidence base of Markov models used to estimate the costs of scaling up antiretroviral programmes in resource-limited settings. <i>BMC Health Services Research</i> , 2010, 10, S3.	2.2	6
222	Clinical deterioration during antituberculosis treatment in Africa: Incidence, causes and risk factors. <i>BMC Infectious Diseases</i> , 2010, 10, 83.	3.0	26
223	Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study. <i>AIDS Research and Therapy</i> , 2010, 7, 23.	1.8	6
224	Prolonged deferral of antiretroviral therapy in the SAPIT trial: Did we need a clinical trial to tell us that this would increase mortality?. <i>South African Medical Journal</i> , 2010, 100, 566.	0.8	11
225	Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. <i>Aids</i> , 2010, 24, 2381-2390.	2.2	335
226	Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. <i>Aids</i> , 2010, 24, 1273-1280.	2.2	84
227	Dissection of Regenerating T-Cell Responses against Tuberculosis in HIV-infected Adults Sensitized by <i>Mycobacterium tuberculosis</i> . <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 674-683.	6.6	60
228	Early and Late Direct Costs in a Southern African Antiretroviral Treatment Programme: A Retrospective Cohort Analysis. <i>PLoS Medicine</i> , 2009, 6, e1000189.	8.4	45
229	Novel Relationship between Tuberculosis Immune Reconstitution Inflammatory Syndrome and Antitubercular Drug Resistance. <i>Clinical Infectious Diseases</i> , 2009, 48, 667-676.	5.7	94
230	Neurologic Manifestations of Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome: A Case Series. <i>Clinical Infectious Diseases</i> , 2009, 48, e96-e107.	5.7	163
231	Early severe morbidity and resource utilization in South African adults on antiretroviral therapy. <i>BMC Infectious Diseases</i> , 2009, 9, 205.	3.0	13
232	Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant <i>Acinetobacter baumannii</i> infections. <i>BMC Infectious Diseases</i> , 2009, 9, 26.	3.0	66
233	Course and complications of varicella zoster ophthalmicus in a high HIV seroprevalence population (Cape Town, South Africa). <i>Eye</i> , 2009, 23, 376-381.	2.3	11
234	Clinical aspects of tuberculosis in HIV-infected adults. , 2009, , 524-531.		2

#	ARTICLE	IF	CITATIONS
235	Deteriorating tuberculosis in a HIV-infected man despite treatmentImmune reconstitution, resistance, or drug malabsorption?. , 2009, , 852-853.		0
236	Effect of Rifampicin on Efavirenz Pharmacokinetics in HIV-Infected Children With Tuberculosis. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 50, 439-443.	2.2	63
237	Effectiveness and Safety of Antiretrovirals with Rifampicin: Crucial Issues for High-Burden Countries. Antiviral Therapy, 2009, 14, 1039-1043.	1.0	47
238	Antiretroviral Therapy Adherence, Virologic and Immunologic Outcomes in Adolescents Compared With Adults in Southern Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 65-71.	2.2	370
239	Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G&gt;T polymorphism on efavirenz concentrations in adults in South Africa. Antiviral Therapy, 2009, 14, 687-695.	1.0	72
240	Patient and provider delay in tuberculosis suspects from communities with a high HIV prevalence in South Africa: A cross-sectional study. BMC Infectious Diseases, 2008, 8, 72.	3.0	74
241	Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infectious Diseases, The, 2008, 8, 516-523.	8.9	696
242	Effect of Rifampicin on Lopinavir Pharmacokinetics in HIV-Infected Children With Tuberculosis. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 566-569.	2.2	114
243	Outcomes of Nevirapine- and Efavirenz-Based Antiretroviral Therapy When Coadministered With Rifampicin-Based Antitubercular Therapy. JAMA - Journal of the American Medical Association, 2008, 300, 530.	7.0	170
244	Impact of enhanced tuberculosis diagnosis in South Africa: A mathematical model of expanded culture and drug susceptibility testing. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 11293-11298.	7.6	88
245	Type 1 Helper T Cells and FoxP3-positive T Cells in HIVâ€“Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 1083-1089.	6.6	141
246	Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. Aids, 2008, 22, 2117-2125.	2.2	67
247	Pharmacy Refill Adherence Compared with CD4 Count Changes for Monitoring HIV-Infected Adults on Antiretroviral Therapy. PLoS Medicine, 2008, 5, e109.	8.4	146
248	HIV Infection Is Associated with a Lower Incidence of Constriction in Presumed Tuberculous Pericarditis: A Prospective Observational Study. PLoS ONE, 2008, 3, e2253.	2.5	34
249	Clinical, Immunological, and Epidemiological Importance of Antituberculosis T Cell Responses in HIV-Infected Africans. Clinical Infectious Diseases, 2007, 44, 1639-1646.	5.7	79
250	Response to â€œCD4 Cell Count Natural History and Informative Censoring in Sub-Saharan Africaâ€“ Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 491.	2.2	0
251	Effect of HIV-1 Infection on T-Cellâ€“based and Skin Test Detection of Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 514-520.	6.6	196
252	Complications of Antiretroviral Therapy in Patients with Tuberculosis: Drug Interactions, Toxicity, and Immune Reconstitution Inflammatory Syndrome. Journal of Infectious Diseases, 2007, 196, S63-S75.	3.9	191

#	ARTICLE	IF	CITATIONS
253	Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 389-393.	3.2	72
254	High Prevalence of Subtherapeutic Plasma Concentrations of Efavirenz in Children. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 45, 133-136.	2.2	83
255	CD4 T-cell responses to combination antiretroviral therapy. <i>Lancet, The</i> , 2007, 370, 366-368.	12.1	7
256	Is it safe to switch between efavirenz and nevirapine in the event of toxicity?. <i>Lancet Infectious Diseases, The</i> , 2007, 7, 733-738.	8.9	43
257	Adherence to Nonnucleoside Reverse Transcriptase Inhibitor-Based HIV Therapy and Virologic Outcomes. <i>Annals of Internal Medicine</i> , 2007, 146, 564.	10.2	324
258	Pharmacogenetics of Efavirenz: Adherence and Virologic Outcomes. <i>Annals of Internal Medicine</i> , 2007, 147, 817.	10.2	0
259	Substitutions Due to Antiretroviral Toxicity or Contraindication in the First 3 years of Antiretroviral Therapy in a Large South African Cohort. <i>Antiviral Therapy</i> , 2007, 12, 753-760.	1.0	118
260	CD4 Decline and Incidence of Opportunistic Infections in Cape Town, South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 464-469.	2.2	160
261	Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole. <i>BMC Infectious Diseases</i> , 2006, 6, 118.	3.0	47
262	Clinical characteristics and initial management of patients with tuberculous pericarditis in the HIV era: the Investigation of the Management of Pericarditis in Africa (IMPI Africa) registry. <i>BMC Infectious Diseases</i> , 2006, 6, 2.	3.0	104
263	Treatment Supporter to Improve Adherence to Antiretroviral Therapy in HIV-Infected South African Adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 43, S127-S133.	2.2	158
264	Adherence to Highly Active Antiretroviral Therapy Assessed by Pharmacy Claims Predicts Survival in HIV-Infected South African Adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 43, 78-84.	2.2	233
265	Quantitative and Functional Differences between Peripheral Blood Myeloid Dendritic Cells from Patients with Pleural and Parenchymal Lung Tuberculosis. <i>Vaccine Journal</i> , 2006, 13, 1299-1306.	3.3	15
266	When to Initiate Highly Active Antiretroviral Therapy in Sub-Saharan Africa? A South African Cost-Effectiveness Study. <i>Antiviral Therapy</i> , 2006, 11, 63-72.	1.0	82
267	Cost-Effectiveness of Highly Active Antiretroviral Therapy in South Africa. <i>PLoS Medicine</i> , 2005, 3, e4.	8.4	111
268	Severe Hepatotoxicity Associated with Nevirapine Use in HIV-Infected Subjects. <i>Journal of Infectious Diseases</i> , 2005, 191, 825-829.	3.9	228
269	Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. <i>Aids</i> , 2004, 18, 887-895.	2.2	476
270	Plasma vitamin A and zinc levels in HIV-infected adults in Cape Town, South Africa. <i>British Journal of Nutrition</i> , 2003, 89, 475-482.	2.7	37



#	ARTICLE	IF	CITATIONS
271	Advances in adult pulmonary tuberculosis. <i>Current Opinion in Pulmonary Medicine</i> , 2002, 8, 173-177.	2.7	13
272	Vertical HIV transmission in South Africa: translating research into policy and practice. <i>Lancet</i> , The, 2002, 359, 992-993.	12.1	21
273	Tuberculosis in the tropics. <i>Clinics in Chest Medicine</i> , 2002, 23, 341-350.	2.2	8
274	Opportunistic infections associated with HIV infection in Africa. <i>Oral Diseases</i> , 2002, 8, 76-79.	3.2	22
275	Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations. <i>Aids</i> , 2001, 15, 1143-1148.	2.2	79
276	Concurrent infections and HIV pathogenesis. <i>Aids</i> , 2000, 14, 2071-2081.	2.2	110
277	Risk Factors for Developing Tuberculosis in HIV-1-Infected Adults From Communities With a Low or Very High Incidence of Tuberculosis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000, 23, 75-80.	2.2	37
278	Thalidomide-Induced Antigen-Specific Immune Stimulation in Patients with Human Immunodeficiency Virus Type 1 and Tuberculosis. <i>Journal of Infectious Diseases</i> , 2000, 181, 954-965.	3.9	56
279	Risk Factors for Developing Tuberculosis in HIV-1-Infected Adults From Communities With a Low or Very High Incidence of Tuberculosis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000, 23, 75-80.	2.2	129
280	Unrecognised <i>Mycobacterium tuberculosis</i> . <i>Lancet</i> , The, 2000, 355, 141.	12.1	1
281	Co-trimoxazole in HIV-1 infection. <i>Lancet</i> , The, 1999, 354, 334-335.	12.1	25
282	Selective Increase in Plasma Tumor Necrosis Factor- $\alpha$ and Concomitant Clinical Deterioration after Initiating Therapy in Patients with Severe Tuberculosis. <i>Journal of Infectious Diseases</i> , 1998, 178, 580-584.	3.9	117
283	CD4 and total lymphocyte counts as predictors of HIV disease progression. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1996, 89, 505-508.	0.5	81
284	Is HIV/AIDS a primary-care disease? Appropriate levels of outpatient care for patients with HIV/AIDS. <i>Aids</i> , 1995, 9, 619-624.	2.2	5
285	Cytolytic T-cell Activity Against Mycobacterial Antigens in HIV. <i>Aids</i> , 1992, 6, 407-412.	2.2	20
286	A comparative study of the polymerase chain reaction and conventional procedures for the diagnosis of tuberculous pleural effusion. <i>Tubercle and Lung Disease</i> , 1992, 73, 262-267.	2.0	79
287	Tuberculous pleural effusions: increased culture yield with bedside inoculation of pleural fluid and poor diagnostic value of adenosine deaminase. <i>Thorax</i> , 1991, 46, 96-99.	7.2	84
288	Miliary tuberculosis: Rapid diagnosis, hematologic abnormalities, and outcome in 109 treated adults. <i>American Journal of Medicine</i> , 1990, 89, 291-296.	1.4	261

#	ARTICLE	IF	CITATIONS
289	Prevention of opportunistic infections in adults. , 0, , 479-488.		0
290	Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive adults. The Cochrane Library, 0, , .	2.8	13
291	AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial. Wellcome Open Research, 0, 6, 33.	1.9	5
292	A multi-parameter diagnostic clinical decision tree for the rapid diagnosis of tuberculosis in HIV-positive patients presenting to an emergency centre. Wellcome Open Research, 0, 5, 72.	1.9	1
293	A comparison of the population pharmacokinetics of rifampicin, isoniazid and pyrazinamide between hospitalized and non-hospitalized tuberculosis patients with or without HIV. Wellcome Open Research, 0, 7, 72.	1.9	0
294	A multi-parameter diagnostic clinical decision tree for the rapid diagnosis of tuberculosis in HIV-positive patients presenting to an emergency centre. Wellcome Open Research, 0, 5, 72.	1.9	2
295	Pharmacokinetic and pharmacogenetic associations with dolutegravir neuropsychiatric adverse events in an African population. Journal of Antimicrobial Chemotherapy, 0, , .	3.2	3
296	Routine antiretroviral pharmacy refill information can predict failure postpartum in previously suppressed South African women living with HIV. Open Forum Infectious Diseases, 0, , .	0.9	0
297	Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis. Wellcome Open Research, 0, 7, 72.	1.9	0
298	Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling. Antimicrobial Agents and Chemotherapy, 0, , .	3.4	1
299	Cerebrospinal Fluid and Tuberculosis Meningitis. Clinical Infectious Diseases, 0, , .	5.7	1
300	Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis. Wellcome Open Research, 0, 7, 72.	1.9	0
301	Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 0, , OF1-OF8.	1.9	0